Zacharon Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Previous attempts at developing glycan-targeting drugs have been hampered by slow and expensive carbohydrate chemistry as well as the lack of effective screening methods. Zacharon Pharmaceuticals has created novel high-throughput screening technology designed to overcome these limitations and it is moving forward with clinical development of its own small-molecule drugs. Its most advanced candidate targets patients with mucopolysaccharidosis, a lysosomal storage disease with numerous subclasses.